|Articles|April 1, 2004
Oral tazarotene improves quality of life
Washington - A new study shows that oral tazarotene (Tazorac; Allergan Inc., Irvine,Calif.) provides significant improvements in quality of life for sufferers of plaque psoriasis. The same study also illustrates the validity of a new measuring tool, PQOL (Psoriasis Quality of Life)-12, for measuring the disease's severity (see related article on Page 35).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5













